$PODD
INSULET CORP Stock $podd

$podd Overview Financials Valuation SEC Filings Company Website

2016 Q2 Form 10-Q Financial Statement

#000114519716000088 Filed on April 29, 2016

Income Statement

Concept	2016 Q2	2016 Q1	2015 Q1
Revenue	$87.33M	$81.21M	$48.15M
YoY Change	44.23%	68.67%	-13.02%
Cost Of Revenue	$36.87M	$37.16M	$18.96M
YoY Change	22.76%	96.05%	-47.86%
Gross Profit	$50.46M	$44.05M	$29.19M
YoY Change	65.35%	50.9%	2.67%
Gross Profit Margin	57.78%	54.24%	60.63%
Selling, General & Admin	$38.79M	$38.76M	$28.25M
YoY Change	19.34%	37.2%	1.21%
% of Gross Profit	76.88%	87.99%	96.78%
Research & Development	$12.95M	$12.99M	$8.207M
YoY Change	7.32%	58.27%	21.07%
% of Gross Profit	25.67%	29.49%	28.11%
Depreciation & Amortization	$3.430M	$3.422M	$3.433M
YoY Change	-6.79%	-0.32%	11.82%
% of Gross Profit	6.8%	7.77%	11.76%
Operating Expenses	$51.75M	$51.75M	$36.46M
YoY Change	16.09%	41.94%	5.09%
Operating Profit	-$1.288M	-$7.699M	-$7.266M
YoY Change	-90.84%	5.96%	285.26%
Interest Expense	-$3.000M	-$2.900M	-$3.200M
YoY Change	-6.25%	-9.38%	-1166.67%
% of Operating Profit
Other Income/Expense, Net	-$2.998M	-$2.926M	-$3.152M
YoY Change	-6.11%	-7.17%	-24.83%
Pretax Income	-$4.286M	-$10.63M	-$10.42M
YoY Change	-75.16%	1.99%	71.38%
Income Tax	$100.0K	$100.0K	$24.00K
% Of Pretax Income
Net Earnings	-$4.198M	-$12.48M	-$11.83M
YoY Change	-72.8%	5.47%	92.61%
Net Earnings / Revenue	-4.81%	-15.37%	-24.58%
Basic Earnings Per Share
Diluted Earnings Per Share	-$73.43K	-$219.3K	-$208.8K
COMMON SHARES
Basic Shares Outstanding	57.16M shares	57.02M shares	56.45M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q2	2016 Q1	2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$111.3M	$111.6M	$145.6M
YoY Change	-23.29%	-23.35%	0.0%
Cash & Equivalents	$75.66M	$111.6M	$145.6M
Short-Term Investments	$35.60M
Other Short-Term Assets	$6.800M	$5.700M	$3.700M
YoY Change	100.0%	54.05%	-47.89%
Inventory	$24.49M	$14.02M	$20.07M
Prepaid Expenses
Receivables	$38.70M	$40.47M	$36.09M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$181.3M	$171.8M	$205.4M
YoY Change	-11.06%	-16.35%	2.79%
LONG-TERM ASSETS
Property, Plant & Equipment	$41.13M	$41.70M	$44.61M
YoY Change	-2.16%	-6.54%	37.03%
Goodwill	$39.76M	$39.76M	$37.54M
YoY Change	5.93%	5.93%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$88.00K	$588.0K	$4.986M
YoY Change	-98.12%	-88.21%	201.82%
Total Long-Term Assets	$81.76M	$82.93M	$100.3M
YoY Change	-15.34%	-17.31%	13.1%
TOTAL ASSETS
Total Short-Term Assets	$181.3M	$171.8M	$205.4M
Total Long-Term Assets	$81.76M	$82.93M	$100.3M
Total Assets	$263.0M	$254.8M	$305.7M
YoY Change	-12.43%	-16.66%	5.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$21.61M	$13.48M	$14.25M
YoY Change	20.59%	-5.36%	-32.11%
Accrued Expenses	$29.94M	$30.39M	$25.27M
YoY Change	13.22%	20.26%	34.61%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.300M	$4.400M	$6.000M
YoY Change	-62.9%	-26.67%	114.29%
Total Short-Term Liabilities	$55.18M	$49.78M	$47.38M
YoY Change	4.74%	5.06%	9.88%
LONG-TERM LIABILITIES
Long-Term Debt	$175.7M	$173.7M	$170.6M
YoY Change	2.01%	1.81%	46.71%
Other Long-Term Liabilities	$4.730M	$4.922M	$3.038M
YoY Change	61.93%	62.01%	53.13%
Total Long-Term Liabilities	$180.4M	$178.6M	$173.6M
YoY Change	3.01%	2.86%	46.82%
TOTAL LIABILITIES
Total Short-Term Liabilities	$55.18M	$49.78M	$47.38M
Total Long-Term Liabilities	$180.4M	$178.6M	$173.6M
Total Liabilities	$235.6M	$228.4M	$225.0M
YoY Change	2.37%	1.51%	35.5%
SHAREHOLDERS EQUITY
Retained Earnings	-$668.2M	-$664.0M	-$589.9M
YoY Change	10.4%	12.57%	10.74%
Common Stock	$57.00K	$57.00K	$57.00K
YoY Change	0.0%	0.0%	3.64%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$27.44M	$26.40M	$80.74M
YoY Change
Total Liabilities & Shareholders Equity	$263.0M	$254.8M	$305.7M
YoY Change	-12.43%	-16.66%	5.96%

Cashflow Statement

Concept	2016 Q2	2016 Q1	2015 Q1
OPERATING ACTIVITIES
Net Income	-$4.198M	-$12.48M	-$11.83M
YoY Change	-72.8%	5.47%	92.61%
Depreciation, Depletion And Amortization	$3.430M	$3.422M	$3.433M
YoY Change	-6.79%	-0.32%	11.82%
Cash From Operating Activities	$3.680M	-$10.52M	-$3.488M
YoY Change	365.82%	201.52%	242.97%
INVESTING ACTIVITIES
Capital Expenditures	-$2.750M	$3.160M	$4.346M
YoY Change	1000.0%	-27.29%	101.48%
Acquisitions
YoY Change
Other Investing Activities	-$34.49M	$4.610M
YoY Change
Cash From Investing Activities	-$37.24M	$1.454M	-$4.346M
YoY Change	14796.0%	-133.46%	101.48%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$796.0K	$4.876M
YoY Change		-83.68%	36.93%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-2.410M	-$2.184M	$2.249M
YoY Change	141.0%	-197.11%	-339.51%
NET CHANGE
Cash From Operating Activities	3.680M	-$10.52M	-$3.488M
Cash From Investing Activities	-37.24M	$1.454M	-$4.346M
Cash From Financing Activities	-2.410M	-$2.184M	$2.249M
Net Change In Cash	-35.97M	-$11.25M	-$5.585M
YoY Change	7719.57%	101.38%	35.79%
FREE CASH FLOW
Cash From Operating Activities	$3.680M	-$10.52M	-$3.488M
Capital Expenditures	-$2.750M	$3.160M	$4.346M
Free Cash Flow	$6.430M	-$13.68M	-$7.834M
YoY Change	518.27%	74.59%	146.82%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q1	dei	Amendment Flag AmendmentFlag	false
CY2016Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2016Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2016Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
CY2016Q1	dei	Document Period End Date DocumentPeriodEndDate	2016-03-31
CY2016Q1	dei	Document Type DocumentType	10-Q
CY2016Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001145197
CY2016Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	57159581	shares
CY2016Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2016Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2016Q1	dei	Entity Registrant Name EntityRegistrantName	INSULET CORP
CY2016Q1	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2016Q1	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2016Q1	dei	Trading Symbol TradingSymbol	PODD
CY2015Q1	podd	Debt Instrument Stated Coupon Rate Interest Expense DebtInstrumentStatedCouponRateInterestExpense	1006000	USD
CY2016Q1	podd	Debt Instrument Stated Coupon Rate Interest Expense DebtInstrumentStatedCouponRateInterestExpense	1006000	USD
CY2015Q1	podd	Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities	-59000	USD
CY2016Q1	podd	Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities	-8776000	USD
CY2015Q1	podd	Interestand Other Expense Total InterestandOtherExpenseTotal	2889000	USD
CY2016Q1	podd	Interestand Other Expense Total InterestandOtherExpenseTotal	2990000	USD
CY2015Q4	podd	Number Of Customers With Greater Than Ten Percent Accounts Receivable Balance NumberOfCustomersWithGreaterThanTenPercentAccountsReceivableBalance	2	customer
CY2016Q1	podd	Number Of Customers With Greater Than Ten Percent Accounts Receivable Balance NumberOfCustomersWithGreaterThanTenPercentAccountsReceivableBalance	2	customer
CY2016Q1	podd	Number Of Financial Institution NumberOfFinancialInstitution	2	location
CY2016Q1	podd	Number Of Inches Of Tubing In Conventional Insulin Pump NumberOfInchesOfTubingInConventionalInsulinPump	42	in
CY2015Q1	podd	Number Of Single Source Suppliers NumberOfSingleSourceSuppliers	1	customer
CY2016Q1	podd	Number Of Single Source Suppliers NumberOfSingleSourceSuppliers	1	customer
CY2015Q1	podd	Percentage Of Accounts Payable Accrued Expensesand Other Current Liabilities PercentageOfAccountsPayableAccruedExpensesandOtherCurrentLiabilities	0.28
CY2016Q1	podd	Percentage Of Accounts Payable Accrued Expensesand Other Current Liabilities PercentageOfAccountsPayableAccruedExpensesandOtherCurrentLiabilities	0.29
CY2016Q1	podd	Product Warranty Term ProductWarrantyTerm	P4Y
CY2016Q1	podd	Return Period ReturnPeriod	P45D
CY2016Q1	podd	Return Period Canada ReturnPeriodCanada	P90D
CY2015Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	36744000	USD
CY2016Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	30385000	USD
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	15213000	USD
CY2016Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	13482000	USD
CY2015Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	4138000	USD
CY2016Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5300000	USD
CY2015Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	5654000	USD
CY2016Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	5755000	USD
CY2015Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	4981000	USD
CY2016Q1	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	3437000	USD
CY2015Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	46668000	USD
CY2016Q1	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	44008000	USD
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	42530000	USD
CY2016Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	40474000	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	36744000	USD
CY2016Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	30385000	USD
CY2015Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	16856000	USD
CY2016Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	11309000	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-654000	USD
CY2016Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-254000	USD
CY2016Q1	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P4Y9M
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	686193000	USD
CY2016Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	690619000	USD
CY2015Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5300000	USD
CY2016Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	3534000	USD
CY2015Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1601000	USD
CY2016Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1702000	USD
CY2015Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	282000	USD
CY2016Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	282000	USD
CY2015Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1883000	USD
CY2016Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1984000	USD
CY2015Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	USD
CY2016Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	USD
CY2015Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8058463	shares
CY2016Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9072274	shares
CY2015Q4	us-gaap	Assets Assets	275126000	USD
CY2016Q1	us-gaap	Assets Assets	254774000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	190761000	USD
CY2016Q1	us-gaap	Assets Current AssetsCurrent	171845000	USD
CY2015Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	9252000	USD
CY2016Q1	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	0	USD
CY2015Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	5519000	USD
CY2016Q1	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	4447000	USD
CY2015Q1	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	5721000	USD
CY2016Q1	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	0	USD
CY2015Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	269000	USD
CY2016Q1	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	0	USD
CY2016Q1	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	4628000	USD
CY2016Q1	us-gaap	Capital Leases Future Minimum Payments Interest Included In Payments CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments	181000	USD
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2016Q1	us-gaap	Capital Leases Future Minimum Payments Next Rolling Twelve Months CapitalLeasesFutureMinimumPaymentsNextRollingTwelveMonths	269000	USD
CY2016Q1	us-gaap	Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments	4447000	USD
CY2016Q1	us-gaap	Capital Leases Future Minimum Payments Remainder Of Fiscal Year CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear	4359000	USD
CY2015Q1	us-gaap	Capital Leases Income Statement Interest Expense CapitalLeasesIncomeStatementInterestExpense	300000	USD
CY2016Q1	us-gaap	Capital Leases Income Statement Interest Expense CapitalLeasesIncomeStatementInterestExpense	200000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	151193000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	145608000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	122672000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	111635000	USD
CY2016Q1	us-gaap	Common Stock Value CommonStockValue	57000	USD
CY2015Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11831000	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12081000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-5585000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-11037000	USD
CY2015Q1	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	1400000	USD
CY2016Q1	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	2000000	USD
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	56954830	shares
CY2016Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	57112482	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	56954830	shares
CY2016Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	57112482	shares
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	57000	USD
CY2015Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	18955000	USD
CY2016Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	37162000	USD
CY2015Q1	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	24000	USD
CY2016Q1	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	75000	USD
CY2014Q3	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	348535	shares
CY2015Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	201250000	USD
CY2016Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	201250000	USD
CY2015Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	25704000	USD
CY2016Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	24002000	USD
CY2015Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	3848000	USD
CY2016Q1	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	3567000	USD
CY2015Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2016Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-11000	USD
CY2015Q4	us-gaap	Deferred Revenue DeferredRevenue	2500000	USD
CY2016Q1	us-gaap	Deferred Revenue DeferredRevenue	1700000	USD
CY2015Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2361000	USD
CY2016Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1461000	USD
CY2015Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3433000	USD
CY2016Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3422000	USD
CY2015Q1	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare	-0.03
CY2016Q1	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare	-0.03
CY2016Q1	us-gaap	Discontinued Operation Intra Entity Amounts Discontinued Operation After Disposal Expense DiscontinuedOperationIntraEntityAmountsDiscontinuedOperationAfterDisposalExpense	300000	USD
CY2016Q1	us-gaap	Discontinued Operation Period Of Continuing Involvement After Disposal DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal	P0Y6M0D
CY2015Q4	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent	1956000	USD
CY2016Q1	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent	0	USD
CY2015Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	0	USD
CY2016Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	210000	USD
CY2016Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	55000000	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1000000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1182000	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1933000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2067000	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	933000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	885000	USD
CY2014	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-23200000	USD
CY2015Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13542000	USD
CY2016Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14739000	USD
CY2015Q4	us-gaap	Goodwill Goodwill	39607000	USD
CY2016Q1	us-gaap	Goodwill Goodwill	39761000	USD
CY2015Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2016Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2015Q1	us-gaap	Gross Profit GrossProfit	29193000	USD
CY2016Q1	us-gaap	Gross Profit GrossProfit	44051000	USD
CY2015	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	9000000	USD
CY2015Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-10418000	USD
CY2016Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-10625000	USD
CY2015Q1	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-10442000	USD
CY2016Q1	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-10689000	USD
CY2015Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.18
CY2016Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.19
CY2015Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-1392000	USD
CY2016Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-1792000	USD
CY2015Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	24000	USD
CY2016Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	64000	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3461000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2306000	USD
CY2015Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	313000	USD
CY2016Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-882000	USD
CY2015Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6966000	USD
CY2016Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2649000	USD
CY2015Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	264000	USD
CY2016Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	956000	USD
CY2015Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-384000	USD
CY2016Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	462000	USD
CY2015Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	3179000	USD
CY2016Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	3096000	USD
CY2015Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	9432000	USD
CY2016Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	10626000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	400000	USD
CY2015Q4	us-gaap	Inventory Net InventoryNet	12024000	USD
CY2015Q4	us-gaap	Liabilities Liabilities	241075000	USD
CY2016Q1	us-gaap	Inventory Net InventoryNet	14024000	USD
CY2015Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	632000	USD
CY2016Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	773000	USD
CY2015Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1960000	USD
CY2016Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	2625000	USD
CY2016Q1	us-gaap	Liabilities Liabilities	228378000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	275126000	USD
CY2016Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	254774000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	65156000	USD
CY2016Q1	us-gaap	Liabilities Current LiabilitiesCurrent	49775000	USD
CY2015Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	5319000	USD
CY2016Q1	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	0	USD
CY2015Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	171698000	USD
CY2016Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	173681000	USD
CY2015Q4	us-gaap	Loss Contingency Accrual Carrying Value Current LossContingencyAccrualCarryingValueCurrent	900000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2249000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2184000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4346000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1454000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3488000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10517000	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-11834000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-12481000	USD
CY2015Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3152000	USD
CY2016Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2926000	USD
CY2015Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2016Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2015Q1	us-gaap	Operating Expenses OperatingExpenses	36459000	USD
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	51750000	USD
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7266000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7699000	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	14270000	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	2181000	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due In Rolling Year Four OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour	2146000	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due In Rolling Year Three OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree	2169000	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due In Rolling Year Two OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo	2162000	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	3934000	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	1678000	USD
CY2015Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	6498000	USD
CY2016Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	7406000	USD
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	76000	USD
CY2016Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	588000	USD
CY2015Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	3000	USD
CY2015Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	3000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	400000	USD
CY2015Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3952000	USD
CY2016Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4922000	USD
CY2015Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	27000	USD
CY2016Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	170000	USD
CY2015Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	0	USD
CY2016Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	139000	USD
CY2015Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1434000	USD
CY2016Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1640000	USD
CY2015Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4346000	USD
CY2016Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3160000	USD
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4283000	USD
CY2016Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5712000	USD
CY2015Q1	us-gaap	Proceeds From Divestiture Of Interest In Consolidated Subsidiaries ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries	0	USD
CY2016Q1	us-gaap	Proceeds From Divestiture Of Interest In Consolidated Subsidiaries ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries	4614000	USD
CY2015Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4876000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	796000	USD
CY2014Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	2614000	USD
CY2015Q1	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	2661000	USD
CY2015Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	4152000	USD
CY2016Q1	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	4160000	USD
CY2015Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	1592000	USD
CY2016Q1	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	1547000	USD
CY2015Q4	us-gaap	Product Warranty Accrual Noncurrent ProductWarrantyAccrualNoncurrent	2560000	USD
CY2016Q1	us-gaap	Product Warranty Accrual Noncurrent ProductWarrantyAccrualNoncurrent	2613000	USD
CY2015Q1	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	420000	USD
CY2016Q1	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	1020000	USD
CY2015Q1	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	467000	USD
CY2016Q1	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	1028000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	41793000	USD
CY2016Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	41695000	USD
CY2015Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	328000	USD
CY2016Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	655000	USD
CY2015Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	1193000	USD
CY2016Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	1340000	USD
CY2015Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8207000	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12989000	USD
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1200000	USD
CY2016Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1200000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-651545000	USD
CY2016Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-664026000	USD
CY2015Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	1163000	USD
CY2016Q1	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	931000	USD
CY2015Q1	us-gaap	Sales Revenue Net SalesRevenueNet	48148000	USD
CY2016Q1	us-gaap	Sales Revenue Net SalesRevenueNet	81213000	USD
CY2015Q1	us-gaap	Segment Reporting Disclosure Of Major Customers SegmentReportingDisclosureOfMajorCustomers	1
CY2016Q1	us-gaap	Segment Reporting Disclosure Of Major Customers SegmentReportingDisclosureOfMajorCustomers	3
CY2015Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	14710000	USD
CY2016Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	24022000	USD
CY2015Q1	us-gaap	Share Based Compensation ShareBasedCompensation	5305000	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	5271000	USD
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	4505202	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1160154	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	29.65
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	777000	USD
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	35647	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	679882	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	12708000	USD
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2999199	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3594297	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	31.37
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	31.31
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	11689000	USD
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3197410	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	16.20
CY2016Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	31.76
CY2016Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	29.94
CY2016Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	6707000	USD
CY2016Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y2M25D
CY2016Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y6M21D
CY2015Q1	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	0	shares
CY2016Q1	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	0	shares
CY2016Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	49137	shares
CY2014Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	12600000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	34051000	USD
CY2016Q1	us-gaap	Stockholders Equity StockholdersEquity	26396000	USD
CY2016Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2015Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	56496648	shares
CY2016Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	57029575	shares
CY2016Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Reclassification of Prior Period Balance</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Certain reclassifications have been made to prior periods amounts to conform to the current period financial statement presentation including adjusting footnotes within to reflect the presentation of discontinued operations. These reclassifications have no effect on previously reported net income.</font></div></div>
CY2016Q1	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nature of the Business</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Insulet Corporation, the "Company," is primarily engaged in the development, manufacturing and sale of its proprietary OmniPod Insulin Management System (the “OmniPod System”), an innovative, discreet and easy-to-use insulin infusion system for people with insulin-dependent diabetes. The OmniPod System features a unique disposable tubeless OmniPod which is worn on the body for approximately three days at a time and the handheld, wireless Personal Diabetes Manager (“PDM”). Conventional insulin pumps require people with insulin-dependent diabetes to learn to use, manage and wear a number of cumbersome components, including up to </font><font style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">42</font><font style="font-family:Arial;font-size:10pt;"> inches of tubing. In contrast, the OmniPod System features two discreet, easy-to-use devices that eliminate the need for a bulky pump, tubing and separate blood glucose meter, provides for virtually pain-free automated cannula insertion, communicates wirelessly and integrates a blood glucose meter. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company acquired Neighborhood Holdings, Inc. and its wholly-owned subsidiaries (collectively, “Neighborhood Diabetes”) in </font><font style="font-family:Arial;font-size:10pt;">June 2011</font><font style="font-family:Arial;font-size:10pt;">. Through Neighborhood Diabetes, the Company provided customers with blood glucose testing supplies, traditional insulin pumps, pump supplies and pharmaceuticals and had the ability to process claims as either durable medical equipment or through pharmacy benefits. In February 2016, the Company sold Neighborhood Diabetes to Liberty Medical LLC ("Liberty Medical"). Additional information regarding the disposition and treatment of the Neighborhood Diabetes business as discontinued operations is provided in note </font><font style="font-family:Arial;font-size:10pt;">3</font><font style="font-family:Arial;font-size:10pt;"> to the consolidated financial statements included in this Form 10-Q.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Commercial sales of the OmniPod System began in the United States in </font><font style="font-family:Arial;font-size:10pt;">2005</font><font style="font-family:Arial;font-size:10pt;">. The Company sells the OmniPod System and other diabetes management supplies in the United States through direct sales to customers or through its distribution partners. The OmniPod System is currently available in multiple countries in Europe, Canada and Israel.</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In addition to using the Pod for insulin delivery, the Company also partners with global pharmaceutical and biotechnology companies to tailor the OmniPod technology platform for the delivery of subcutaneous drugs across multiple therapeutic areas.    </font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In July 2015, the Company executed an asset purchase agreement whereby it acquired the Canadian OmniPod distribution operations from GlaxoSmithKline ("GSK"). With the acquisition, the Company assumed all distribution, sales, marketing, training and support activities for the OmniPod system in Canada.</font></div></div>
CY2016Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Use of Estimates in Preparation of Financial Statements</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions in the application of certain of its significant accounting policies that may materially affect the reported amounts of assets, liabilities, equity, revenue and expenses. The most significant estimates used in these financial statements include the valuation of stock-based compensation expense, acquired businesses, accounts receivable, inventories, goodwill, deferred revenue, equity instruments, the lives of property and equipment and intangible assets, as well as warranty and doubtful accounts allowance reserve calculations. Actual results may differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001145197-16-000088-index-headers.html	Edgar Link	pending
0001145197-16-000088-index.html	Edgar Link	pending
0001145197-16-000088.txt	Edgar Link	pending
0001145197-16-000088-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
podd-20160331.xml	Edgar Link	completed
podd-20160331.xsd	Edgar Link	pending
podd-20160331_cal.xml	Edgar Link	unprocessable
podd-20160331_def.xml	Edgar Link	unprocessable
podd-20160331_lab.xml	Edgar Link	unprocessable
podd-20160331_pre.xml	Edgar Link	unprocessable
podd-2016x03x31_10q.htm	Edgar Link	pending
podd-exx101_20160331x10q.htm	Edgar Link	pending
podd-exx102_20160331x10q.htm	Edgar Link	pending
podd-exx103_20160331x10q.htm	Edgar Link	pending
podd-exx104_20160331x10q.htm	Edgar Link	pending
podd-exx311_20160331x10q.htm	Edgar Link	pending
podd-exx312_20160331x10q.htm	Edgar Link	pending
podd-exx321_20160331x10q.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PODD
INSULET CORP Stock $podd

2016 Q2 Form 10-Q Financial Statement

#000114519716000088 Filed on April 29, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PODD INSULET CORP Stock $podd

2016 Q2 Form 10-Q Financial Statement

#000114519716000088 Filed on April 29, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PODD
INSULET CORP Stock $podd